ArticleFrontiers in aging neuroscience2026
SVIP in plasma: a candidate blood-based biomarker for early detection of amnestic mild cognitive impairment.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Amnestic mild cognitive impairment (aMCI) represents a critical clinical window for early intervention in Alzheimer's disease (AD). Identifying readily detectable, high-abundance plasma biomarkers for aMCI remains clinically important. Overexpression of Valosin-Containing Protein (VCP) has been shown to enhance autophagy and reduce tau levels in AD animal models. Notably, VCP, with a molecular weight of 90 kDa, typically assembles into hexamers, which is hypothesized to restrict its ability to cross the blood-brain barrier even under neurodegenerative conditions. In contrast, the small VCP-interacting protein (SVIP), with a molecular weight of only 9 kDa, interacts with VCP to maintain the dynamic stability of autophagosomes within cells. Therefore, we aim to explore plasma SVIP as a peripheral blood biomarker for aMCI and assess whether it can outperform VCP in detecting aMCI. Methods: This was a retrospective study based on the STAR (Shenzhen Multi-modal Aging Research) cohort. Participants were recruited as a convenience sample. Eighty-four participants (44 cognitively unimpaired [CU], 40 aMCI) were included, with diagnostic classification based on standardized clinical and neuropsychological criteria. Plasma levels of SVIP and VCP were measured using deep plasma proteomics enriched with biofunctional magnetic beads. Diagnostic performance was evaluated using Receiver Operating Characteristic (ROC) analysis and DeLong's test. This study was registered in the Chinese Clinical Trial Registry (ChiCTR2200066700). Results: Compared to the CU group, the aMCI group showed significantly decreased SVIP ( Conclusion: Plasma SVIP demonstrates significantly higher diagnostic accuracy than VCP for the detection of aMCI, suggesting its potential as a candidate blood-based biomarker pending large-scale pathophysiological validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.